Insider Selling: ArthroCare Corp. Director Sells 10,000 Shares of Stock (ARTC)
ArthroCare Corp. (NASDAQ:ARTC) Director Barbara Boyan sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $45.00, for a total transaction of $450,000.00. Following the transaction, the director now directly owns 24,525 shares in the company, valued at approximately $1,103,625. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
ArthroCare Corp. (NASDAQ:ARTC) traded up 0.65% during mid-day trading on Friday, hitting $46.48. The stock had a trading volume of 291,460 shares. ArthroCare Corp. has a 52 week low of $31.56 and a 52 week high of $49.95. The stock’s 50-day moving average is $39.10 and its 200-day moving average is $36.20. The company has a market cap of $1.319 billion and a P/E ratio of 72.95.
ArthroCare Corp. (NASDAQ:ARTC) last announced its earnings results on Wednesday, October 30th. The company reported $0.27 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.27. The company had revenue of $91.86 million for the quarter, compared to the consensus estimate of $88.99 million. During the same quarter last year, the company posted $0.27 earnings per share. ArthroCare Corp.’s revenue was up 5.7% compared to the same quarter last year. On average, analysts predict that ArthroCare Corp. will post $1.44 earnings per share for the current fiscal year.
ARTC has been the subject of a number of recent research reports. Analysts at Northcoast Research downgraded shares of ArthroCare Corp. from a “buy” rating to a “neutral” rating in a research note to investors on Thursday. Separately, analysts at Canaccord Genuity raised their price target on shares of ArthroCare Corp. from $48.00 to $56.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of ArthroCare Corp. from $38.00 to $47.00 in a research note to investors on Wednesday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ArthroCare Corp. has a consensus rating of “Buy” and a consensus target price of $49.67.
ArthroCare Corporation (NASDAQ:ARTC), is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.